CHICAGO, April 28, 2025 /PRNewswire/ — New research published in Cancer Research and presented today at the AACR Annual Meeting 2025 shows that an AI-led cancer triage platform, C the Signs, significantly improved early cancer detection rates while reducing pressure on the NHS.
The study, which evaluated over 235,000 patient risk assessments conducted across 1,084 GP practices between January 2020 and September 2024, found that:
C the Signs uses AI to analyse clinical data in under 60 seconds — identifying patients at risk, recommending the most appropriate pathway, and streamlining cancer diagnosis. By helping clinicians focus resources where they are needed most, the platform is delivering tangible results for patients, GPs, and the health system.
The findings come at a critical time for the NHS, following Lord Darzi’s Independent Review highlighting poor cancer survival rates in England compared to other high-income countries. The research also aligns with national efforts, such as Keir Starmer’s AI manifesto, to leverage homegrown technologies for major public health challenges.
“Cancer is a race against time. Every day we wait is a day lost,” said Dr Bea Bakshi, CEO & Co-Founder of C the Signs. “This study shows that with the right technology, we can shift the odds — finding cancer earlier, improving outcomes, and giving patients more time with the people they love. It’s proof that AI, when built responsibly and used thoughtfully, can transform healthcare for the better. We’re proud to work alongside the NHS, clinicians, and communities to make early detection the new standard, not the exception.”
About C the Signs
C the Signs is an AI-powered cancer prediction platform founded by NHS doctors to help identify patients at risk of cancer at the earliest, most treatable stage. Built on real-world evidence and clinical insight, C the Signs is deployed across the NHS and US healthcare systems, supporting GPs, oncologists, and health systems to improve early detection, enhance equity, and save lives. The platform is a UKCA-marked medical device and integrates seamlessly with major EMRs.
For more information, visit www.cthesigns.com or contact hello@cthesigns.com
Photo: https://healthtechnologynet.com/wp-content/uploads/2025/04/CtheSigns_AI_platform.jpg
SOURCE C the Signs
Novel Endoscopic Procedure Demonstrates Substantial and Durable Reduction in Insulin Resistance and Improvement in Beta…
Slimjaro Slimjaro Lakeland, FL, May 03, 2025 (GLOBE NEWSWIRE) -- SlimJaro Canada: The Revolutionary Fat-Burning…
Discover why Javy Protein Coffee is the best protein coffee for energy, recovery, and flavor.…
PURCHASE, N.Y., May 02, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader…
Dallas, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- In a historic medical achievement, the National…
STOCKHOLM, May 3, 2025 /PRNewswire/ -- At this week's ESTRO conference in Vienna, RaySearch Laboratories…